1[1]Calle EE,Rodriguez C,Thurmond KW,et al .Overweight,obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults [J] . Engl Med, 2003,348:1 625.
2[2]Schwartz MW,Woods SC,Porte DJ ,et al .Central nervous system control of food intake[J].Nature ,2000,404(6 778) :661.
3[3]Kernan WN,Viscoli CM,Brass LM,et al .Phenylpropanolamine and the risk of hemorrhagic stroke[J].Engl Med, 2000,343:1 826.
4[4]Gardin JM,Schumacher D,Constantine G,et al .Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/ fenfluramine [J] . JAMA, 2000,283:1 703.
5[5]Fanghanel G,Cortinas L,Sanchez RL,et al .A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity[J]. Int J Obes Relat Metab Disord , 2000,24:144.
6[6]Dujovne CA,Zavoral J H,Rowe E, et al .Effects of sibutramine on body weight and serum lipids: a double blind, randomized, placebo- controlled study in 322overweight and obese pationts with dys lipidemia[J].Am Heart J ,2001,142(3) :489.
7[7]Smith IG,Goulder MA.Randomized place be controlled trial of long termtreatment with sibutramine in mild to moderate obesity[J] . Fam Pract, 2001,50: 505.
8[8]Hauptman J .Orlistat: selectiveinhibition of caloricab sorption can affect long term bodyweight [J].Endocrine, 2000,13: 201.
9[9]Lucas KH, Kaplan - Machlis B.Orlistat, a novel weight loss therapy [J] . Ann Pharmacother, 2001,35(3): 314.
10[10]Thomas ET,Daniel GP, Carol M, et al.Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss [J]. Am Gastroenterol, 2001,96(6): 1 888.
